{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:33:35Z","timestamp":1780515215562,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40266-025-01244-y","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T10:24:40Z","timestamp":1756808680000},"page":"1045-1055","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Medication Use and Quality of Life in Older Adults with Personality Disorders"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0279-4137","authenticated-orcid":false,"given":"Julie E. M.","family":"Schulkens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7085-3349","authenticated-orcid":false,"given":"Sebastiaan P. J.","family":"van Alphen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1567-2881","authenticated-orcid":false,"given":"Lara","family":"Stas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Louter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8307-8406","authenticated-orcid":false,"given":"Frans R. J.","family":"Verhey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6351-0479","authenticated-orcid":false,"given":"Sjacko","family":"Sobczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"issue":"2","key":"1244_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1192\/bjp.2019.166","volume":"216","author":"C Winsper","year":"2020","unstructured":"Winsper C, et al. The prevalence of personality disorders in the community: a global systematic review and meta-analysis. Br J Psychiatry. 2020;216(2):69\u201378.","journal-title":"Br J Psychiatry"},{"issue":"9","key":"1244_CR2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s40263-021-00852-7","volume":"35","author":"JC Pascual","year":"2021","unstructured":"Pascual JC, Mart\u00edn-Blanco A, Soler J. Twenty-year trends in the psychopharmacological treatment of outpatients with borderline personality disorder: a cross-sectional naturalistic study in Spain. CNS Drugs. 2021;35(9):1023\u201332.","journal-title":"CNS Drugs"},{"issue":"4","key":"1244_CR3","first-page":"583","volume":"41","author":"R Shah","year":"2018","unstructured":"Shah R, Zanarini MC. Comorbidity of borderline personality disorder: current status and future directions. Psychiatr Clin. 2018;41(4):583\u201393.","journal-title":"Psychiatr Clin"},{"issue":"7","key":"1244_CR4","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00115-021-01139-4","volume":"92","author":"F Jacobi","year":"2021","unstructured":"Jacobi F, et al. Disease burden of borderline personality disorder: cost of illness, somatic comorbidity and mortality. Nervenarzt. 2021;92(7):660\u20139.","journal-title":"Nervenarzt"},{"issue":"2","key":"1244_CR5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1037\/a0028709","volume":"4","author":"AD Powers","year":"2013","unstructured":"Powers AD, Oltmanns TF. Borderline personality pathology and chronic health problems in later adulthood: the mediating role of obesity. Personal Disord. 2013;4(2):152.","journal-title":"Personal Disord"},{"key":"1244_CR6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00228-014-1796-5","volume":"71","author":"G Hefner","year":"2015","unstructured":"Hefner G, et al. Side effects related to potentially inappropriate medications in elderly psychiatric patients under everyday pharmacotherapy. Eur J Clin Pharmacol. 2015;71:165\u201372.","journal-title":"Eur J Clin Pharmacol"},{"key":"1244_CR7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00228-020-03012-w","volume":"77","author":"G Hefner","year":"2021","unstructured":"Hefner G, et al. Potentially inappropriate medication in older psychiatric patients. Eur J Clin Pharmacol. 2021;77:331\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1244_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):1\u201310.","journal-title":"BMC Geriatr"},{"key":"1244_CR9","unstructured":"Op den Camp S, et al. Adverse childhood events, personality disorders, and multimorbidity in older adults: exploring the connections. Clin Gerontol. 2025:1\u201312."},{"issue":"6","key":"1244_CR10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ejim.2011.08.029","volume":"22","author":"A Nobili","year":"2011","unstructured":"Nobili A, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med. 2011;22(6):597\u2013602.","journal-title":"Eur J Intern Med"},{"key":"1244_CR11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.archger.2018.06.018","volume":"78","author":"L Mid\u00e3o","year":"2018","unstructured":"Mid\u00e3o L, et al. Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe. Arch Gerontol Geriatr. 2018;78:213\u201320.","journal-title":"Arch Gerontol Geriatr"},{"issue":"4","key":"1244_CR12","doi-asserted-by":"crossref","first-page":"E130","DOI":"10.1503\/cmaj.141219","volume":"187","author":"W-H Lu","year":"2015","unstructured":"Lu W-H, et al. Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: a retrospective cohort study. CMAJ. 2015;187(4):E130\u20137.","journal-title":"CMAJ"},{"issue":"6","key":"1244_CR13","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.japh.2017.06.002","volume":"57","author":"N Leelakanok","year":"2017","unstructured":"Leelakanok N, et al. Association between polypharmacy and death: a systematic review and meta-analysis. J Am Pharm Assoc. 2017;57(6):729-738. e10.","journal-title":"J Am Pharm Assoc"},{"issue":"8","key":"1244_CR14","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jamda.2018.04.008","volume":"19","author":"DL Vetrano","year":"2018","unstructured":"Vetrano DL, et al. Association of polypharmacy with 1-year trajectories of cognitive and physical function in nursing home residents: results from a multicenter European study. J Am Med Dir Assoc. 2018;19(8):710\u20133.","journal-title":"J Am Med Dir Assoc"},{"issue":"9","key":"1244_CR15","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jama.289.9.1107","volume":"289","author":"JH Gurwitz","year":"2003","unstructured":"Gurwitz JH, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107\u201316.","journal-title":"JAMA"},{"issue":"10","key":"1244_CR16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016358","volume":"7","author":"NN Dhalwani","year":"2017","unstructured":"Dhalwani NN, et al. Association between polypharmacy and falls in older adults: a longitudinal study from England. BMJ Open. 2017;7(10): e016358.","journal-title":"BMJ Open"},{"issue":"29\u201330","key":"1244_CR17","first-page":"508","volume":"116","author":"T Kratz","year":"2019","unstructured":"Kratz T, Diefenbacher A. Psychopharmacological treatment in older people: avoiding drug interactions and polypharmacy. Dtsch Arztebl Int. 2019;116(29\u201330):508\u201318.","journal-title":"Dtsch Arztebl Int"},{"issue":"8","key":"1244_CR18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40264-016-0422-0","volume":"39","author":"L Rolfes","year":"2016","unstructured":"Rolfes L, et al. The impact of experiencing adverse drug reactions on the patient\u2019s quality of life: a retrospective cross-sectional study in the Netherlands. Drug Saf. 2016;39(8):769\u201376.","journal-title":"Drug Saf"},{"issue":"10","key":"1244_CR19","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1007\/s11136-019-02214-9","volume":"28","author":"K Haraldstad","year":"2019","unstructured":"Haraldstad K, et al. A systematic review of quality of life research in medicine and health sciences. Qual Life Res. 2019;28(10):2641\u201350.","journal-title":"Qual Life Res"},{"issue":"12","key":"1244_CR20","first-page":"983","volume":"80","author":"International Health Conference","year":"2003","unstructured":"International Health Conference. Constitution of the world health organization. 1946. Bull World Health Organ. 2003;80(12):983.","journal-title":"Bull World Health Organ"},{"issue":"3","key":"1244_CR21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213263","volume":"14","author":"KM Van Leeuwen","year":"2019","unstructured":"Van Leeuwen KM, et al. What does quality of life mean to older adults? A thematic synthesis. PLoS ONE. 2019;14(3): e0213263.","journal-title":"PLoS ONE"},{"issue":"3","key":"1244_CR22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/HRP.0b013e3182937116","volume":"21","author":"WW IsHak","year":"2013","unstructured":"IsHak WW, et al. Quality of life in borderline personality disorder. Harv Rev Psychiatry. 2013;21(3):138\u201350.","journal-title":"Harv Rev Psychiatry"},{"key":"1244_CR23","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s11136-019-02149-1","volume":"28","author":"TF Crocker","year":"2019","unstructured":"Crocker TF, et al. Quality of life is substantially worse for community-dwelling older people living with frailty: systematic review and meta-analysis. Qual Life Res. 2019;28:2041\u201356.","journal-title":"Qual Life Res"},{"key":"1244_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s41999-024-01036-4","author":"C Falke","year":"2024","unstructured":"Falke C, et al. The association between medication use and health-related quality of life in multimorbid older patients with polypharmacy. Eur Geriatr Med. 2024. https:\/\/doi.org\/10.1007\/s41999-024-01036-4.","journal-title":"Eur Geriatr Med"},{"issue":"3","key":"1244_CR25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/1745509X.4.3.311","volume":"4","author":"M Boustani","year":"2008","unstructured":"Boustani M, et al. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311\u201320.","journal-title":"Aging Health"},{"issue":"5","key":"1244_CR26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, Charro Fd. EQ-SD: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343.","journal-title":"Ann Med"},{"issue":"28","key":"1244_CR27","first-page":"1574","volume":"149","author":"L Lamers","year":"2005","unstructured":"Lamers L, et al. Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff. Ned Tijdschr Geneeskd. 2005;149(28):1574\u20138.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"1244_CR28","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s11136-005-1743-0","volume":"14","author":"KL Haywood","year":"2005","unstructured":"Haywood KL, Garratt AM, Fitzpatrick R. Quality of life in older people: a structured review of generic self-assessed health instruments. Qual Life Res. 2005;14:1651\u201368.","journal-title":"Qual Life Res"},{"key":"1244_CR29","doi-asserted-by":"crossref","unstructured":"Schuurman LJ, et al. Psychometric properties of the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication-Adult-Aged-Spectrum (SCOP-A). 2024.","DOI":"10.1002\/hup.70009"},{"issue":"2","key":"1244_CR30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul F, et al. G* power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175\u201391.","journal-title":"Behav Res Methods"},{"issue":"4","key":"1244_CR31","doi-asserted-by":"crossref","first-page":"21725","DOI":"10.4088\/JCP.16m10713","volume":"78","author":"DT Maust","year":"2017","unstructured":"Maust DT, et al. National trends in antidepressant, benzodiazepine, and other sedative-hypnotic treatment of older adults in psychiatric and primary care. J Clin Psychiatry. 2017;78(4):21725.","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"1244_CR32","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/arclin\/acx120","volume":"33","author":"SF Crowe","year":"2018","unstructured":"Crowe SF, Stranks EK. The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis. Arch Clin Neuropsychol. 2018;33(7):901\u201311.","journal-title":"Arch Clin Neuropsychol"},{"issue":"1","key":"1244_CR33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/ap.12360","volume":"54","author":"S Hannaford","year":"2019","unstructured":"Hannaford S, Shaw R, Walker R. Older adults\u2019 perceptions of psychotherapy: what is it and who is responsible? Aust Psychol. 2019;54(1):37\u201345.","journal-title":"Aust Psychol"},{"issue":"6","key":"1244_CR34","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/cpp.2900","volume":"30","author":"DA Khasho","year":"2023","unstructured":"Khasho DA, et al. The effectiveness of individual schema therapy in older adults with borderline personality disorder: a multiple-baseline case series design. Clin Psychol Psychother. 2023;30(6):1313\u201323.","journal-title":"Clin Psychol Psychother"},{"issue":"6","key":"1244_CR35","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1080\/13607863.2017.1318260","volume":"22","author":"AC Videler","year":"2018","unstructured":"Videler AC, et al. Schema therapy for personality disorders in older adults: a multiple-baseline study. Aging Ment Health. 2018;22(6):738\u201347.","journal-title":"Aging Ment Health"},{"issue":"4","key":"1244_CR36","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1016\/S2666-7568(24)00001-1","volume":"5","author":"MS Veenstra-Spruit","year":"2024","unstructured":"Veenstra-Spruit MS, et al. Group schema therapy combined with psychomotor therapy for older adults with a personality disorder: an open-label, multicentre, randomised controlled trial. Lancet Healthy Longev. 2024;5(4):e245\u201354.","journal-title":"Lancet Healthy Longev"},{"key":"1244_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-5-33","volume":"5","author":"CA Wolfs","year":"2007","unstructured":"Wolfs CA, et al. Performance of the EQ-5D and the EQ-5D+ C in elderly patients with cognitive impairments. Health Qual Life Outcomes. 2007;5:1\u201310.","journal-title":"Health Qual Life Outcomes"},{"key":"1244_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12877-015-0167-0","volume":"16","author":"A-S Helvik","year":"2016","unstructured":"Helvik A-S, et al. Health-related quality of life in older depressed psychogeriatric patients: one year follow-up. BMC Geriatr. 2016;16:1\u20139.","journal-title":"BMC Geriatr"},{"issue":"7","key":"1244_CR39","doi-asserted-by":"crossref","first-page":"932","DOI":"10.4088\/JCP.v65n0709","volume":"65","author":"A Hofer","year":"2004","unstructured":"Hofer A, et al. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry. 2004;65(7):932\u20139.","journal-title":"J Clin Psychiatry"},{"key":"1244_CR40","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-0447.2008.01310.x","volume":"119","author":"P Bebbington","year":"2009","unstructured":"Bebbington P, et al. Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand. 2009;119:22\u20138.","journal-title":"Acta Psychiatr Scand"},{"issue":"52","key":"1244_CR41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF03085663","volume":"7","author":"C Dijk","year":"2009","unstructured":"Dijk C, Verheij R, Schellevis F. Polyfarmacie bij ouderen. Huisarts Wet. 2009;7(52):315\u2013315.","journal-title":"Huisarts Wet"},{"issue":"3","key":"1244_CR42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214240","volume":"14","author":"MP Oktora","year":"2019","unstructured":"Oktora MP, et al. Trends in polypharmacy and dispensed drugs among adults in the Netherlands as compared to the United States. PLoS ONE. 2019;14(3): e0214240.","journal-title":"PLoS ONE"},{"key":"1244_CR43","unstructured":"Centraal Bureau voor de Statistiek. Enqu\u00eate Beroepsbevoling (EBB). 2023. 2-8-2023. Available from: https:\/\/www.cbs.nl\/nl-nl\/onze-diensten\/methoden\/onderzoeksomschrijvingen\/korte-onderzoeksbeschrijvingen\/enquete-beroepsbevolking--ebb--."},{"issue":"18","key":"1244_CR44","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1503\/cmaj.131873","volume":"186","author":"C Frank","year":"2014","unstructured":"Frank C, Weir E. Deprescribing for older patients. CMAJ. 2014;186(18):1369\u201376.","journal-title":"CMAJ"},{"key":"1244_CR45","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.734045","volume":"12","author":"M Kurczewska-Michalak","year":"2021","unstructured":"Kurczewska-Michalak M, et al. Polypharmacy management in the older adults: a scoping review of available interventions. Front Pharmacol. 2021;12: 734045.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1244_CR46","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-000833","volume":"2","author":"BA Golomb","year":"2012","unstructured":"Golomb BA, et al. The older the better: are elderly study participants more non-representative? A cross-sectional analysis of clinical trial and observational study samples. BMJ Open. 2012;2(6): e000833.","journal-title":"BMJ Open"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01244-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01244-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01244-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T01:04:48Z","timestamp":1761699888000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01244-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1244"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01244-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received no funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Medical Ethics Committee of Zuyderland Medical Center (METCZ20180104).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent prior to enrolment in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors read and approved the final manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are available from the corresponding author, J.S., upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The codes are available from the corresponding author, J.S., upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by J. Schulkens, S. van Alphen, and S. Sobczak. The first draft of the manuscript was written by J. Schulkens and all authors commented on previous versions of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}